{"id":7872,"date":"2016-02-26T10:21:31","date_gmt":"2016-02-26T10:21:31","guid":{"rendered":"http:\/\/revoscience.com\/en\/?p=7872"},"modified":"2016-02-26T10:21:31","modified_gmt":"2016-02-26T10:21:31","slug":"genetically-engineered-immune-cell-therapy-found-to-boost-survival-in-mice-with-brain-tumors","status":"publish","type":"post","link":"https:\/\/www.revoscience.com\/en\/genetically-engineered-immune-cell-therapy-found-to-boost-survival-in-mice-with-brain-tumors\/","title":{"rendered":"Genetically Engineered Immune Cell Therapy Found to Boost Survival in Mice with Brain Tumors"},"content":{"rendered":"

A research team led by Nagoya University, Japan, shows in mice the potential of a special immune cell that targets a key protein in tumor growth that helps stop brain cancer.<\/strong><\/em><\/span><\/p>\n

\n

\"<\/a>
Chimeric antigen receptor (CAR) T Cells targeting podoplanin in mouse brain tumors.<\/figcaption><\/figure>\n

Japan<\/strong> \u2013 For decades most cancers have been treated with a core standard of treatments that include surgery, radiation, and chemotherapy. Now, immunotherapy\u2014a type of treatment that harnesses the patient\u2019s immune system to combat the disease\u2014represents the future of cancer treatment, with its efficacy being demonstrated in even the most aggressive types of cancer.<\/span>

Brain cancer comes in many forms, ranging from more easily treatable benign forms that may trigger gradual loss of brain functions, to malignant forms that can in many cases prove fatal. While there have been improvements in the current standard treatments, patients with glioblastoma (GBM), the most common and aggressive form of brain tumor, still suffer from a median survival rate of only 14.6 months and 5-year overall survival rates of less than 10%. There is therefore pressing need for novel therapies that improve the outcomes.<\/span>

Researchers at Nagoya University have been studying the therapeutic effect of T cells, vital disease-fighting components in our body\u2019s immune system, for fighting cancer.<\/span>

<\/p>\n

[pullquote]Researchers at Nagoya University have been studying the therapeutic effect of T cells, vital disease-fighting components in our body\u2019s immune system, for fighting cancer.[\/pullquote]<\/p>\n

\u201cImmunotherapy has emerged in recent years as a promising strategy for treatment of GBM,\u201d says Atsushi Natsume, corresponding author of the study and a member of the Nagoya University School of Medicine\u2019s Department of Neurosurgery. \u201cWe have successfully engineered T cells that produce special receptors on their surface, called chimeric antigen receptors (CARs), which allow the T cells to recognize specific proteins (antigens) expressed in GBM. We designed chimeric antigen receptor (CAR) T cells that specifically target podoplanin (PDPN), a key protein for the progression of solid tumors, including GBM.\u201d<\/span>

The research team found that injection of CAR T cells into 79 immunodeficient mice arrested the growth of GBM in 60% of them. Furthermore, the T cells can recognize PDPN on the tumor surface even with the absence of the body\u2019s own immune recognition system, which is usually compromised in cancer.<\/span>

\u201cConsidering that PDPN is associated with poor prognosis in GBM, CAR T-cell therapy that targets this protein is promising for treatment of patients with relapsed or resistant tumors following first-line chemotherapy,\u201d says Toshihiko Wakabayashi, a coauthor and the chair of Department of Neurosurgery Nagoya University School of Medicine. \u201cThere are certainly challenges to overcome for clinical application of this kind of immunotherapy, but the newly published data are an important milestone in immunotherapy targeting solid tumors that have eluded other treatments.\u201d<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

A research team led by Nagoya University, Japan, shows in mice the potential of a special immune cell that targets a key protein in tumor growth that helps stop brain cancer.<\/p>\n","protected":false},"author":6,"featured_media":7873,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17],"tags":[],"class_list":["post-7872","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research"],"featured_image_urls":{"full":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",300,245,false],"thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340-150x150.jpg",150,150,true],"medium":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",300,245,false],"medium_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",300,245,false],"large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",300,245,false],"1536x1536":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",300,245,false],"2048x2048":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",300,245,false],"ultp_layout_landscape_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",300,245,false],"ultp_layout_landscape":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",300,245,false],"ultp_layout_portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",300,245,false],"ultp_layout_square":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",300,245,false],"newspaper-x-single-post":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",300,245,false],"newspaper-x-recent-post-big":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",300,245,false],"newspaper-x-recent-post-list-image":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",80,65,false],"web-stories-poster-portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",300,245,false],"web-stories-publisher-logo":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",96,78,false],"web-stories-thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/02\/3340.jpg",150,123,false]},"author_info":{"info":["Amrita Tuladhar"]},"category_info":"Research<\/a>","tag_info":"Research","comment_count":"0","_links":{"self":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/7872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/comments?post=7872"}],"version-history":[{"count":0,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/7872\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media\/7873"}],"wp:attachment":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media?parent=7872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/categories?post=7872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/tags?post=7872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}